Adma Biologics (ADMA) Current Deferred Revenue (2014 - 2025)
Adma Biologics' (ADMA) quarterly Current Deferred Revenue came in at $143000.0 in Q2 2025, down 87.35% YoY from $1.1 million in Q2 2024, and little changed on a QoQ basis from $143000.0 in Q1 2025.
Adma Biologics (ADMA) Current Deferred Revenue (2014 - 2025) Analysis & Trends
Adma Biologics (ADMA) has 12 years of Current Deferred Revenue data on file, last reported at $143000.0 in Q2 2025.
- Quarterly Current Deferred Revenue fell 87.35% year-over-year to $143000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $143000.0 (down 87.35% YoY) and the FY2024 annual result came in at $143000.0, down 21.43% from the prior year.
- Current Deferred Revenue steadied at $143000.0 in Q2 2025, from $143000.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $1.1 million in Q2 2024 to a low of $142834.0 in Q1 2021.
- A 5-year average of $254074.4 and a median of $142834.0 in 2021 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2024 — Current Deferred Revenue surged 691.13% — and 2025, when it plunged 87.35%.
- Tracing ADMA's Current Deferred Revenue over 5 years: stood at $142834.0 in 2021, then gained by 0.12% to $143000.0 in 2022, then climbed by 27.27% to $182000.0 in 2023, then slipped by 21.43% to $143000.0 in 2024, then changed by 0.0% to $143000.0 in 2025.
- The last three Current Deferred Revenue figures came in at $143000.0 (Q2 2025), $143000.0 (Q1 2025), and $143000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 143,000.00 |
| Mar 31, 2025 | 143,000.00 |
| Dec 31, 2024 | 143,000.00 |
| Sep 30, 2024 | 143,000.00 |
| Jun 30, 2024 | 1.13 Mn |
| Mar 31, 2024 | 1.12 Mn |
| Dec 31, 2023 | 182,000.00 |
| Sep 30, 2023 | 142,834.00 |
| Jun 30, 2023 | 142,834.00 |
| Mar 31, 2023 | 142,834.00 |
| Dec 31, 2022 | 143,000.00 |
| Sep 30, 2022 | 142,834.00 |
| Jun 30, 2022 | 142,834.00 |
| Mar 31, 2022 | 142,834.00 |
| Dec 31, 2021 | 142,834.00 |
| Sep 30, 2021 | 142,834.00 |
| Jun 30, 2021 | 142,834.00 |
| Mar 31, 2021 | 142,834.00 |
| Dec 31, 2020 | 142,834.00 |
| Sep 30, 2020 | 142,834.00 |